Latest News & Features
article
A project decades in the making, the Unified Patent Court and Unitary Patent promise to change the European IP landscape, writes Marisa Woutersen. 1 June 2023
Big Pharma
A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue. 30 May 2023
article
Court outlines submission method in the event of CMS failure | Hard-copy format requirements include USB stick and delivery to Luxembourg | Guidelines have “made people nervous” say lawyers | Full details on how to submit. 30 May 2023
Medtech
Medtronic prior art reference does not qualify, says Federal Circuit | Firm was hoping to invalidate five catheter technology patents. 25 May 2023
Big Pharma
Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents. 25 May 2023
Big Pharma
Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children. 23 May 2023
Big Pharma
Case concerned the interpretation of a key requirement of the US Patent Act | Amgen’s ‘roadmap’ held to describe step-by-step its own trial-and-error method for finding functional antibodies. 18 May 2023
Big Pharma
The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account. 18 May 2023
Big Pharma
The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments. 18 May 2023
article
The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market. 16 May 2023